Roche Holding AG (RHHBY), a Swiss healthcare major, on Monday said that it has concluded the previously announced acquisition of LumiraDx Limited's (LMDX) Point of Care technology, after receiving all the required antitrust and regulatory approvals.
LumiraDx is a point of care diagnostics firm with a focus on community-based healthcare.
LumiraDx's Point of Care solution will complement Roche's diagnostics portfolio across clinical chemistry, immunochemistry, coagulation and molecular, and across multiple disease areas.
Matt Sause, CEO of Roche Diagnostics, said: "Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are confident that the LumiraDx platform and technology will help us expand the availability of testing, especially in settings such as primary care and low and middle income countries."
Roche will now embark on the full integration of the its multi-assay point of care platform and the related research and development, operational, and commercial sites into its global organization.
Under the terms of the deal announced last year, Roche had agreed to pay an acquisition price of $295 million and an additional payment of up to $55 million for the reimbursement of amounts to fund the Point of Care technology platform business until the closing of the deal.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.